Oryzon Genomics Reports 95% Response Rate in AML Trial
In the July 2026 ALICE-2 data cut, 19 efficacy-evaluable patients had a 95% ORR and 84% CRc. Twelve-month overall survival was 76% after a median follow-up of eight months.
Related stories
General Motors shares hit record high, up 4%
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC
SolarEdge Reports Q3 Revenue of $326.1 Million, Adjusted EPS of $0.29
Third-quarter revenue was $326.1 million, in line with the midpoint of prior guidance. Adjusted EPS was $0.29 versus FactSet consensus of $0.04. SolarEdge forecast fourth-quarter r
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC
Kempower Reports Q3 Revenue Decline and Lowers 2026 Guidance
Kempower reported a 10% revenue decline and negative operative EBIT in Q3 2026, citing weakening charging investment. It lowered full-year 2026 guidance, while reporting a €128 mil
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC
Skue Sparebank Reports Q3 Pretax Profit of NOK 102.5 Million
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC
Microsoft Shares Hit Record High, Up 6.1%
M impact | EQUITY | Nov 04, 2026, 03:32 PM UTC
IMFA Q2 Profit Jumps 51% to Rs 149 Crore
Indian Metals & Ferro Alloys Ltd reported Q2 FY27 profit after tax of Rs 148.77 crore, compared with Rs 98.77 crore a year earlier. Revenue rose 35%.
M impact | EQUITY | Nov 04, 2026, 03:32 PM UTC